Business Context and Reporting Period
Company: Vyome Holdings, Inc. (formerly ReShape Lifesciences Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: September 2, 2025
Reporting Period: The filing primarily addresses the completion of a merger on August 15, 2025, and provides financial data for the quarter ended June 30, 2025, for the acquired entity, Vyome Therapeutics, Inc.
Key Financial Metrics
This Form 8-K serves as a disclosure vehicle to incorporate financial statements by reference into a shelf registration statement (Form S-3). The text of the filing itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity.
- Revenue/Profit/Cash Flow: Not provided in the filing text; referenced in Exhibit 99.1 and 99.2.
- Debt/Liquidity: Not provided in the filing text; referenced in Exhibit 99.1 and 99.3.
- Pro Forma Data: Unaudited pro forma condensed combined financial statements are included as Exhibit 99.3 but specific figures are not listed in the main text.
Material Changes
The primary material change reported is the completion of a business combination:
- Merger Completion: On August 15, 2025, the Company completed the merger with Vyome Therapeutics, Inc. pursuant to the Merger Agreement dated July 8, 2024.
- Corporate Structure: Raider Lifesciences Inc. (Merger Sub) merged with and into Vyome Therapeutics, Inc., with Vyome surviving as a wholly-owned subsidiary.
- Rebranding: Effective before the open of trading on August 15, 2025, the parent company was renamed "Vyome Holdings, Inc."
Guidance, Outlook, and Risks
The filing does not contain specific management commentary, forward-looking guidance, or a detailed risk factor analysis within the main text.
- Purpose of Filing: The report is filed to incorporate Vyome's financial statements and MD&A (Exhibits 99.1 and 99.2) and pro forma statements (Exhibit 99.3) into the Company's existing shelf registration statement (File No. 333-287168).
- Emerging Growth Company: The registrant has indicated it is an emerging growth company.
Investor Verification Checklist
- Review Exhibit 99.1 for Vyome Therapeutics' actual financial statements for the quarter ended June 30, 2025.
- Review Exhibit 99.2 for Management's Discussion and Analysis (MD&A) regarding Vyome's financial condition.
- Review Exhibit 99.3 for the unaudited pro forma condensed combined financial statements reflecting the merger.
- Verify the status of the shelf registration statement (Form S-3, File No. 333-287168) to understand the capital raising context.
- Confirm the trading symbol "HIND" on The Nasdaq Capital Market reflects the post-merger entity.